524348 logo

Aarti Drugs Limited Stock Price

BSE:524348 Community·₹38.8b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

524348 Share Price Performance

₹0
-458.75 (-100.00%)
₹628.00
Fair Value
₹0
-458.75 (-100.00%)
Price ₹0

524348 Community Narratives

AnalystConsensusTarget·
Fair Value ₹628 32.3% undervalued intrinsic discount

USFDA And MHRA Approvals Will Unlock New Global Markets

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

Trending Discussion

Updated Narratives

524348 logo

USFDA And MHRA Approvals Will Unlock New Global Markets

Fair Value: ₹628 32.3% undervalued intrinsic discount
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
4 Rewards

Aarti Drugs Limited Key Details

₹24.8b

Revenue

₹15.9b

Cost of Revenue

₹8.9b

Gross Profit

₹6.9b

Other Expenses

₹2.0b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
21.81
35.75%
8.04%
38.9%
View Full Analysis

About 524348

Founded
1984
Employees
1284
CEO
Prakash Patil
WebsiteView website
www.aartidrugs.co.in

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Recent 524348 News & Updates

Recent updates

No updates